Table 2.

Primary outcome: carotid-femoral pulse wave velocity (m/s)

Outcome	n	Vitamin K Mean (SD)	n	Placebo Mean (SD)	Unadjusted Treatment effect (95% CI)	P	Adjusted Treatment effecta (95% CI)	P
6 mo	57	11.7 (3.2)	63	11.1 (3.1)	0.56 (−0.58 to 1.70)	0.33	0.12 (−0.66 to 0.90)	0.76
12 mo	55	11.7 (3.2)	59	11.7 (3.6)	−0.03 (−1.31 to 1.25)	0.96	−0.12 (−0.93 to 0.69)	0.77
Repeated measures	—	—	—	—	—	—	0.01 (−0.66 to 0.68)	0.98
Multiple imputation (12 mo)	—	—	—	—	—	—	−0.11 (−0.89 to 0.68)	0.79
Sensitivity analysisb (6 mo)	70	11.6 (3.3)	78	11.1 (3.1)	0.52 (−0.53 to 1.57)	0.33	0.20 (−0.51 to 0.90)	0.59

^aAdjusted for age, sex, eGFR, site, and baseline values.

^bIncludes participants removed from main analysis due to uncertainty about medication content.